BrightGene Unveils Encouraging Phase 1 Results of BGM0504 for Obesity Treatment in China and the U.S. BrightGene has reported positive topline Phase 1 results for its oral obesity treatment BGM0504, showing safety and preliminary efficacy in both China and the U.S.

BrightGene Unveils Encouraging Phase 1 Results of BGM0504 for Obesity Treatment in China and the U.S. #China #Suzhou #BrightGene #BGM0504 #ObesityDrug

BrightGene Unveils Promising Results for GLP-1R/GIPR Agonist in Diabetes and Obesity Treatment BrightGene Pharmaceutical has shared groundbreaking Phase 2 data on its dual GLP-1R/GIPR agonist for type 2 diabetes and weight management, along with innovative amylin analog research.

BrightGene Unveils Promising Results for GLP-1R/GIPR Agonist in Diabetes and Obesity Treatment #China #Suzhou #diabetes #BrightGene #BGM0504

BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments BrightGene reveals positive Phase 2 trial results for its dual GLP-1R/GIPR agonist BGM0504 and a new amylin analogue, showcasing significant potential in diabetes management.

BrightGene's Phase 2 Study Data Reveals Promising Weight Management Treatments #China #Suzhou #BrightGene #BGM0504 #BGM1812

BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment BrightGene Pharmaceutical unveiled encouraging Phase-2 results at the ADA Conference, highlighting its dual-GLP-1R/GIPR agonist's potential against Type-2 Diabetes and obesity.

BrightGene Unveils Promising Phase-2 Data for Weight Regulation and Type-2 Diabetes Treatment #China #Suzhou #BrightGene #BGM0504 #BGM1812

BrightGene Unveils Promising Phase 2 Data on Its Dual Agonist for Weight Management and Type 2 Diabetes BrightGene Pharmaceutical Company presents significant Phase 2 findings for its dual GLP-1R/GIPR agonist aimed at tackling weight management and Type 2 diabetes, showcasing potential advancements in treatment options.

BrightGene Unveils Promising Phase 2 Data on Its Dual Agonist for Weight Management and Type 2 Diabetes #China #Suzhou #diabetes_treatment #BrightGene #BGM0504

BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments BrightGene has announced positive Phase 2 results for BGM0504, a new dual GLP-1R/GIPR agonist, and preclinical data for BGM1812, showcasing their potential in weight management and diabetes treatment.

BrightGene Unveils Promising Phase 2 Data for Weight Management and Diabetes Treatments #China #Suzhou #BrightGene #BGM0504 #BGM1812